Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Diagnostic
- Imaging
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372581
For the Licensee of Germanys Development Option, Licensor grants the exclusive right and option, the Development Option, to acquire a license to further develop and commercialize products based upon, derived from or incorporating a Thrombus Compounds, after completion of the Clinical Proof of Concept Study for such Thrombus Compounds, each a Licensee Option Product.
Licensor grants a non-exclusive worldwide license under the Licensor Patent Rights and Licensor Technology, to the extent required, and an exclusive, worldwide license under Licensor’s interests in the Joint Patent Rights and Joint Technology, each with the right to grant sublicenses, to permit Licensee to develop, have developed, to make, have made, use, have used, sell, offer for sale, have sold, import, and have imported Licensee Option Products, each, thereafter, a Licensee Licensed Product in the Territory during the License Term, for any and all uses within the Field.
x-2104R shall mean Licensors proprietary MRI enhancing agent, a Thrombus Compound.
IPSCIO Record ID: 382411
Included in this agreement is this grant back of patents and technology to permit this Licensee to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, import, and have imported Licensee Licensed Products in the Territory, for any and all uses within the Field.
— Licensor of Germany grants a non-exclusive, worldwide license in the Field under the Licensor Patent Rights and Licensor Technology, and Licensor’s interests in the Joint Patent Rights and Joint Technology, for the sole purpose of conducting the activities required in the performance of Licensee’s obligations under the Proof of Concept Development Program, and,
— subject to Licensor’s failure to exercise the Development Option or in the event Licensee terminates this Agreement, a non-exclusive, worldwide license under the Licensor Patent Rights and the Licensor Technology, to the extent required, and an exclusive license under Licensor’s interests in the Joint Patent Rights and Joint Technology, each with the right to grant sublicenses, to permit Licensee to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, import, and have imported Licensees Licensed Products in the Territory, for any and all uses within the Field.
US Patents
5,560,903
5,021,236
4,647,447
4,963,344
5,362,475
5,648,063
IPSCIO Record ID: 26505
MRI Products shall mean magnetic resonance imaging products incorporating one or more Thrombus Ligands and one or more MRI-Based Chelate Compounds and which are marketed and sold for the Imaging Field.
Peptidic Thrombus Ligands shall mean any pepetidic compounds discovered during the Research Program, and any analogs or derivatives thereof, which bind to fibrin and have potential utility for identifying and localizing thrombi IN VIVO.
IPSCIO Record ID: 133546
Licensor grants the German Licensee the exclusive right and license under the Patent Rights, Technology, Joint Patent Rights and Joint Program Technology to develop, use, offer for sale, sell, have sold, import and have imported Licensed Products in the Territory for use in the Field, and to manufacture or have manufactured Compound MS-325 and Licensed Products (to the extent manufacture of Compound MS-325 and Licensed Products is covered by the Manufacturing Agreement, manufacture by or on behalf of Licensee, with the right to sublicense.
Licensed Product shall mean any product comprising Compound MS-325.
IPSCIO Record ID: 237237
With this Agreement, Licensor discharges, releases, promises and covenants not to sue, threaten to sue or otherwise disturb Licensee, and its Affiliates, and any Licensees Licensee, subcontractor, supplier, distributor, vendor, reseller, purchaser, or user of the MR Contrast Agent Product, acquired directly or indirectly from Licensee {or its Affiliates) or a Licensees Licensee in any country in the world, for any claim or cause of action based upon the Licensor MR Intellectual Property and the manufacture, use, Sale, advertisement, offer for Sale, importation, lease, or otherwise transfer or disposition of the MR Contrast Agent Product, whether such claim or cause of action is presently known or unknown.
Licensor is recognized for his expertise in clinical magnetic resonance imaging and magnetic resonance angiography and as the inventor of contrast-enhanced magnetic resonance angiography techniques.
MR Imaging System{s) means any magnetic resonance transmission/receiving system, inclusive of all hardware (for example, without limitation, imaging coils) and software components, that is capable of performing CE-MRA procedures.
IP relates to the magnetic resonance imaging drug, MS-325.
MS-325 is designed to provide visual imaging of the vascular system, through a type of MRI known as magnetic resonance angiography, or MRA.
MS-325 is specifically designed to enhance the quality of magnetic resonance images of the arteries and veins and to provide physicians with a superior method for diagnosing vascular disease.
IPSCIO Record ID: 237211
For License to Licensor Leads, Collaboration Leads and Licensee Leads, Licensor grants an exclusive worldwide license, with the right to grant sublicenses, to use the Licensor Leads, Collaboration Leads and Licensee Leads and Collaboration Results pursuant to a Collaboration Project or a Licensee Project to research, develop, make, have made, use, import and have sold Licensed Products in the Diagnostic Imaging Field.
For the Option in the Licensee Therapeutics Field, the License Option, with regard to any Licensor Lead for which a Collaboration Project exists and for any Collaboration Lead or Licensee Lead, Licensee may extend the license rights granted to the exclusive use of such lead to research, develop, make, have made, use, import and have sold Licensed Products in the Licensee Therapeutics Field and will have a non-exclusive license to use the Licensor Technology in the Licensee Therapeutics Field in connection therewith; provided that such lead is not part of an active Licensor research and development program or that Licensor is not precluded from granting the license because of an agreement with a third party.
Licensor Technology shall mean collectively any proprietary peptide, protein and antibody library technology and/or all related materials, data, know-how, inventions and Patent Rights that Licensor owns or controls and has the right to grant licenses to in the Diagnostic Imaging Field existing or arising during and through the Research Term.
Licensor Leads shall mean any peptide, protein or antibody molecules existing as of the Effective Date, including Proteases, Antibodies, Blood Proteins , Cell Surface Receptors·, Signal Transduction Components, and, Viruses, and any peptide, protein or antibody molecules that Licensor thereafter owns or controls and has the right to grant licenses in the Diagnostic Imaging Field after the Effective Date for so long as Licensee maintains the exclusive license to the Licensor Technology in the Diagnostic Imaging Field, and any data, know-how, inventions and Patent Rights pertaining to such Licensor Leads. Licensor Leads shall not include any Collaboration Leads.
Collaboration Leads shall mean any peptide, protein or antibody molecule and the sequence contained therein and derivatives thereof, resulting from or pertaining to any Collaboration Project commenced during the Research Term and that exist at the time of termination of the Research Term and associated Patent Rights, other than Licensor Leads.
Licensee Leads shall mean any peptide, protein or antibody molecule and the sequence contained therein and derivatives thereof discovered by Licensee after the Research Term using any of the Licensor Technology or Licensor Improvements and associated Patent Rights.
Collaboration Results shall mean any Collaboration Leads and other materials, information, data, and know-how, whether or not patentable, that result from any Collaboration Project that is useful by Licensee in the Collaboration Field or by Licensor in all fields except the Collaboration Field, and any Patent Rights covering inventions resulting from such Collaboration Project, excluding Licensor Technology and Licensor Improvements and Barriers Carrier and Licensee Improvements.
Licensed Product shall mean any product that consists of, includes or was derived from any Licensor Lead, Collaboration Lead or Licensee Lead for which Formal Development has commenced or which arose out of a Collaboration Project.
Diagnostic Imaging Field shall mean any in vivo use in medical imaging, including radiopharmaceutical, ultrasound, MRI and X-ray and light imaging.
Licensee possesses intellectual property, technology and expertise relating to the research, development and commercialization of diagnostic imaging products and radiopharmaceuticals.
